Donor NK cells for children with relapsed B-cell leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing an experimental treatment using natural killer (NK) cells from a donor to fight a type of childhood leukemia called B-cell ALL that has come back or not responded to usual treatments. The hope is that these cells can help destroy the leukemia cells and put the cancer into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 3 and 18 years old.
- Has B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment.
- Leukemia cells must test positive for a marker called CD19.
- Expected to live at least 3 more months.
- Must be well enough to meet safety checks for heart, lungs, liver, and kidneys.
- No active serious infections or uncontrolled other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Hear when a new Relapsed/Refractory Pediatric B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.